Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10893MR)

This product GTTS-WQ10893MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10893MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4959MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ5765MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ3906MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ394MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ9112MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ4533MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ15770MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ3768MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW